



(11)

EP 3 184 546 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 16/28 ^(2006.01) **C07K 14/72** ^(2006.01)

(48) Corrigendum issued on:
30.10.2019 Bulletin 2019/44

(45) Date of publication and mention
of the grant of the patent:
17.07.2019 Bulletin 2019/29

(21) Application number: **16199717.6**

(22) Date of filing: **18.12.2009**

(54) **HUMAN CGRP RECEPTOR BINDING ANTIBODIES**

AN DEN HUMANEN CGRP-REZEPTOR BINDENDE ANTIKÖRPER

ANTICORPS SE LIANT AU RÉCEPTEUR CGRP HUMAIN

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR
Designated Extension States:
AL BA RS

(30) Priority: **23.12.2008 US 203569 P**
25.11.2009 US 264622 P

(43) Date of publication of application:
28.06.2017 Bulletin 2017/26

(60) Divisional application:
19181187.6

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
09775072.3 / 2 379 594

(73) Proprietor: **Amgen Inc.**
Thousand Oaks, California 91320-1799 (US)

(72) Inventors:
• **BOONE, Thomas Charles**
Newbury Park CA 91320 (US)

- **BRANKOW, David W.**
Northridge CA 91326 (US)
- **GEGG, Colin V., Jr.**
Camarillo, CA 93012 (US)
- **HU, Shaw-Fen Sylvia**
Thousand Oaks, CA 91360 (US)
- **King, Chadwick T.**
Noreth Vancouver, BC V7L 3T5 (CA)
- **LU, Hsieng Sen**
Thousand Oaks, CA 91362 (US)
- **SHI, Licheng**
Newbury Park, CA 91320 (US)
- **XU, Cen**
Newbury Park, CA 91320 (US)

(74) Representative: **Grünecker Patent- und**
Rechtsanwälte
PartG mbB
Leopoldstraße 4
80802 München (DE)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 184 546 B8

(56) References cited:

- **MCLATCHIE L M ET AL:** "RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.", **NATURE** 28 MAY 1998, vol. 393, no. 6683, 28 May 1998 (1998-05-28), pages 333-339, XP002767658, ISSN: 0028-0836
- **Committee on Methods of Producing Monoclonal Antibodies**, Institute for Laboratory Animal Research, National Research Council: "Monoclonal Antibody Production", 1999, National Academy Press, Washington, DC, XP002767659, ISBN: 0-309-51904-7 * page 10 *
- **TAYLOR CHRISTOPHER K ET AL:** "PHARMACOLOGICAL CHARACTERIZATION OF NOVEL ALPHA-CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR PEPTIDE ANTAGONISTS THAT ARE SELECTIVE FOR HUMAN CGRP RECEPTORS", **JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS**, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 319, no. 2, 1 November 2006 (2006-11-01), pages 749-757, XP009084228, ISSN: 0022-3565
- **DAVIS CARL D ET AL:** "The Tortuous Road to an Ideal CGRP Function Blocker for the Treatment of Migraine", **CURRENT TOPICS IN MEDICINAL CHEMISTRY**, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 8, no. 16, 1 November 2008 (2008-11-01), pages 1468-1479, XP008119816, ISSN: 1568-0266
- **CHAUHAN M ET AL:** "Studies on the effects of the N-terminal domain antibodies of calcitonin receptor-like receptor and receptor activity-modifying protein 1 on calcitonin gene-related peptide-induced vasorelaxation in rat uterine artery.", June 2004 (2004-06), **BIOLOGY OF REPRODUCTION** JUN 2004, VOL. 70, NR. 6, PAGE(S) 1658 - 1663, XP002571487, ISSN: 0006-3363 * the whole document *
- **DURHAM PAUL L:** "CGRP-RECEPTOR ANTAGONISTS--A FRESH APPROACH TO MIGRAINE THERAPY?", **NEW ENGLAND JOURNAL OF MEDICINE**, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 11, 11 March 2004 (2004-03-11), pages 1073-1075, XP009082423, ISSN: 1533-4406
- **TEPPER STEWART ET AL:** "Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial", **LANCET NEUROLOGY**, LANCET PUBLISHING GROUP, LONDON, GB, vol. 16, no. 6, 28 April 2017 (2017-04-28), pages 425-434, XP085003376, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(17)30083-2